Treatment drug for autoimmune diseases and allergic diseases
View Patent ↗The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.
1. A method for the prophylaxis and/or therapy of a disease associated with Th17 cells in a subject, comprising administering an effective amount of an anti-Embigin antibody having cytotoxicity or cytotoxicity inducing activity to the subject, wherein the disease associated with Th17 cells is selected from the group consisting of multiple sclerosis, psoriasis, rheumatism, chronic noninfectious uveitis, and glomerulonephritis.
2. The method according to claim 1 , wherein the anti-Embigin antibody has cytotoxicity inducing activity.
3. The method according to claim 2 , wherein the subclass of the anti-Embigin antibody having cytotoxicity inducing activity is IgG1, IgG3 or IgM.
4. The method according to claim 1 , wherein the anti-Embigin antibody has cytotoxicity.
5. The method according to claim 4 , wherein the anti-Embigin antibody having cytotoxicity is conjugated with a cytotoxic substance, a chemotherapeutic agent or a radioisotope.
6. The method according to claim 1 , wherein the disease is multiple sclerosis.
7. A method for delivering a cytotoxic drug to a Th17 cell in a subject with a disease associated with Th17 cells, comprising administering to the subject an anti-Embigin antibody conjugated with the cytotoxic drug, wherein the disease associated with Th17 cells is selected from the group consisting of multiple sclerosis, psoriasis, rheumatism, chronic noninfectious uveitis, and glomerulonephritis.
8. The method according to claim 7 , wherein the cytotoxic drug is a cytotoxic substance, a chemotherapeutic agent or a radioisotope.